Aroma Bit Receives Additional Capital Investment Funding From Epson X Investment, Kyocera, and TechAccel Ventures
Aroma Bit, Inc., (Representative Director & CEO: Shunichiro Kuroki, headquarters: Chuo-ku, Tokyo), develops and markets compact odor imaging sensors and various related innovative services, has allocated additional shares to third-parties. The purpose of the funding is to acquire growth funds needed for future functionality enhancements of the company’s compact odor sensors and development of mass production capabilities, business development, and etc. EB-GB Limited Partnership funded by Epson X Investment Corporation (Representative Director: Yasunori Ogawa, headquarters: Chiyoda-ku, Tokyo), Kyocera Corporation (President: Hideo Tanimoto, headquarters: Kyoto City, Kyoto), and TechAccel investment limited partnership 1 (fund operated by TechAccel Ventures, LLC (Functional Manager: Masatoshi Ohba, headquarters: Minato-ku, Tokyo)) are the investment partners participating in this new capital investment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005274/en/
Silicon CMOS type Smell Sensor Development Kit (Product ID: 5C-SSM) (Photo: Business Wire)
Aroma Bit, Inc.: http://www.aromabit.com
Purpose and background of the increased capital investment: Support for acceleration of the compact odor sensors’ mass production and expansion of the digital odor sensing market
Aroma Bit has developed the world’s first compact odor imaging sensor that digitizes odors with visualization patterns from various odor inputs, similar to an animal’s sense of smell. It differs from conventional gas sensors, which can only detect specific substances.
Despite COVID-19, Aroma Bit has seen an increase in business negotiations with customers both in Japan and internationally accelerated by emerging trends such as smart technology, contactless technology, and digital transformation (DX).
Furthermore, the device has a wide range of applications, including the food, agriculture, daily commodities, industrial machinery, mobility, healthcare, robotics, mobile information service, home electronics, and IoT industries. With market applications exceeding initial expectations, there is considerable potential demand for odor digitization using Aroma Bit’s innovative technology.
After this third-party allocation of new shares, Aroma Bit plans to collaborate with major electronic device companies with advanced manufacturing expertise to accelerate development and mass production of compact odor sensor technologies.
Additionally, Aroma Bit plans to strengthen development of new products and services that leverage the company’s proprietary odor databases, and expand its sales and marketing worldwide.
In the future, Aroma Bit will continue to pursue its vision of “Enrich Society by Creating a World where Odors and Aromas are Visualized through Digital Odor Sensing Technology.”
Release of development kit for silicon CMOS compact odor sensors
Aroma Bit launched its silicon CMOS sensor module development kit [5C-SSM-H1] in January of 2021. Those sensors feature 80 elements arranged on a 6 mm x 3 mm silicon chip (5 types of odor-sensitive membrane x 16 elements per membrane). Aroma Bit Silicon Sensor Technology, Inc., a subsidiary of Aroma Bit manages sales for these devices.
With the release of the silicon CMOS odor sensor, Aroma Bit anticipates increased demand in high-volume consumer applications such as mobile devices, mobility, and home electronics, where its other QCM odor sensor use was previously difficult due to factors such as price and usage environment.
About Aroma Bit
Aroma Bit is a company that plans, develops, and sells electronic devices such as compact odor sensors as well as innovative new services that use these devices.
|
[Company Profile] |
||
|
Company name: |
|
Aroma Bit, Inc. |
|
Location: |
|
Sagami Bldg. 2F, 7-13-6 Ginza, Chuo-ku, Tokyo |
|
Representative: |
|
Representative Director & CEO Shunichiro Kuroki |
|
Established: |
|
February 2014 |
|
Business: |
|
Development, production, and sales of electronic equipment and systems including compact odor imaging sensors |
|
|
|
Planning, development, and sales of products and innovative services that use the sensor products |
|
|
|
Other business related to the above |
|
URL: www.aromabit.com |
||
About Epson X Investment
Epson X Investment Corporation is a Corporate Venture Capital (CVC) firm wholly owned by information equipment and precision instrument manufacturer Seiko Epson Corporation. It established the “EP-GB Investment Limited Partnership” with independent venture capital firm Global Brain Corporation, which has strengths in CVC operations, as general partner and is conducting investment activities.
URL: https://www.epson-exi.com/
Kyocera Corporation (TOKYO:6971, https://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2020, the company’s consolidated sales revenue totaled 1.6 trillion yen (approx. US$14.7 billion). Kyocera is ranked #549 on Forbes magazine’s 2020 “Global 2000” list of the world’s largest publicly traded companies.
About TechAccel Ventures
TechAccel Ventures, LLC is a venture capital firm established and operated by Omron, Ricoh, and SMBC Venture Capital. It invests mainly in tech venture companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005274/en/
Contact information
[Inquiries regarding this announcement]
Aroma Bit, Inc.
Public Relegations Department (Matsumoto, Osamu)
TEL: +81-3-4455-4609 / Email: info@aromabit.com
Epson X Investment Corporation
Seiko Epson PR & IR Department (Muto, Nobuo)
TEL: +81-266-58-1705 or +81-3-5368-0961 / Email: info@press.epson.co.jp
KYOCERA Corporation
Corporate Communications (Usami, Masaru)
TEL: +81-75-604-3514 / Email: webmaster.cc@kyocera.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom